FrancophonIA/ELRC3.0 huggingface dataset:
English: If this dose has been well tolerated it may be increased in weekly intervals and according to the clinical status of the patient to 1.0 mg or 2.5 mg.
Maltese: Jekk din id-doża tkun tollerata sew tista' tiżdied f'intervalli ta' ġimgħa u skont l-istat kliniku tal-pazjent għal 1.0 mg jew 2.5 mg.
English: - if you undergo LDL apheresis with dextrane sulphate.
Maltese: - jekk tagħmel tneħħija ta' LDL b'dextrane sulphate.
English: “Vascace is indicated for the treatment of hypertension.”
Maltese: “Vascace huwa indikat għat-trattament tal-pressjoni għolja.”
English: Second and third trimesters of pregnancy (see sections 4.4. and 4.6)
Maltese: It-tieni u t-tielet trimestri tat-tqala (ara sezzjonijiet 4.4 u 4.6)
English: Others
Maltese: MEMBRI
English: Angioedema has been associated with ACE inhibitors, with a reported incidence of 0.1-0.5%.
Maltese: Anġjoedima ġiet assoċjata ma' inibituri ta' ACE, b'inċidenza rrappurtata ta' 0.1-0.5%.
English: Cilazapril is efficiently absorbed and rapidly converted to the active form, cilazaprilat.
Maltese: Cilazapril huwa assorbit b'mod effiċjenti u jinbidel malajr għall-forma attiva, cilazaprilat.
English: Rarely, neutropenia and agranulocytosis have been associated with ACE inhibitors, especially in patients with renal failure or collagen vascular disease, and those receiving immunosuppressive therapy.
Maltese: Rarament, newtropenija u agranuloċitosi kienu assoċjati ma' inibituri ta' ACE, speċjalment f'pazjenti b'insuffiċjenza renali jew mard tal-collagen vaskulari, u dawk li qed jirċievu terapija immunosoppressiva.
English: The usual dose range of Vascace is 2.5 to 5.0 mg once daily.
Maltese: Il-medda normali taddoża ta' Vascace hija ta' 2.5 sa 5.0 mg darba kuljum.
English: Gold
Maltese: Billi
English: Dry mouth, aphthous stomatitis, decreased appetite, diarrhoea, vomiting Rare
Maltese: Ħalq xott, stomatite bl-ulċeri, tnaqqis fl-aptit, dijarea, rimettar Rari
English: Section 4.5 - Interaction with other medicinal products and other forms of interaction The most important possible interactions (PK, PD or toxic) have been included in the harmonized label, since these drugs are frequently co-prescribed with cilazapril or other ACE inhibitors and scientific rationale is available.
Maltese: Sezzjoni 4.5 - Effett fuq prodotti mediċinali oħrajn u forom oħra ta' effetti li jista' jkun hemm L-aktar effetti possibbli importanti (PK, PD jew tossiċi) ġew inklużi fit-tikketta armonizzata, minħabba li dawn il-mediċini spiss jingħataw flimkien ma' cilazapril jew inibituri ACE oħrajn u lloġika xjentifika hija disponibbli.
English: The CHMP was of the view that it should be mentioned that the angiotensin escape phenomenon (renin-angiotensin system activation and increased activity in sympathetic system) can occur (and was observed) in patients treated with ACE inhibitors as monotherapy (Roig e, et al Eur.
Maltese: Is-CHMP kien tal-opinjoni li għandu jissemma li jista' jseħħ (u kien osservat) il-fenomenu ta' ħarba tal-angiotensin (l-attivazzjoni tas-sistema tar-renin-angiotensin u żieda fl-attività fis-sistema simpatetika) f'pazjenti ttrattati b'inibituri ACE bħala monoterapija (Roig e, et al Eur.
English: The antihypertensive effect of Vascace is usually apparent within the first hour after administration, with maximum effect observed between 3 and 7 hours after dosing.
Maltese: L-effett ta' tnaqqis fil-pressjoni ta' Vascace normalment jidher fl-ewwel siegħa wara l-għoti, b'effett massimu osservat bejn 3 u 7 sigħat wara d-dożaġġ.
English: Low-density lipoproteins (LDL) apheresis: Patients receiving ACE inhibitors during LDL apheresis with dextran sulphate have experienced life-threatening anaphylaxis.
Maltese: Aferesi ta' lipoproteini ta' densità baxxa (LDL): Pazjenti li qed jirċievu inibituri ta' ACE matul aferesi ta' LDL b'dextran sulphate esperjenzaw anafilassi ta' periklu għall-ħajja.
English: Skin and subcutaneous tissue disorders
Maltese: Disturbi muskolu-skeletrali u tat-tessut konnettiv
English: In such patients a lower starting dose (0.5mg) is recommended and the initiation of treatment should take place under medical supervision.
Maltese: F'pazjenti bħal dawn hija rrakkomandata doża inizjali aktar baxxa (0.5mg) u t-trattament għandu jinbeda taħt sorveljanza medika.
English: Dizziness
Maltese: Dijabete
English: Hypertension: The initial dose is 1 mg/day.
Maltese: Id-doża tal-bidu hija 1 mg/kuljum.
English: Hypertensive patients receiving diuretics: If possible, the diuretic should be discontinued 2 - 3 days before beginning therapy with Vascace to reduce the likelihood of symptomatic hypotension.
Maltese: Jekk ikun possibbli, id-dijuretiku għandu jitwaqqaf 2 - 3 ijiem qabel tibda l-kura b'Vascace biex titnaqqas il-possibbiltà ta' pressjoni baxxa sintomatika.
English: Section 4.2 - Posology and method of administration
Maltese: Sezzjoni 4.6 - Tqala u treddiegħ
English: “Chronic heart failure: Therapy with Vascace should be initiated at a recommended starting dose of 0.5 mg once daily under close medical supervision.
Maltese: “Insuffiċjenza kronika tal-qalb: It-terapija b'Vascace għandha tinbeda b'doża inizjali rakkomandata ta' 0.5 mg darba kuljum taħt sorveljanza medika stretta.
English: - Your doctor will then increase your dose until your blood pressure is under control - the usual maintenance dose is between 2.5 mg and 5 mg per day.
Maltese: - Wara t-tabib tiegħek iżid id-doża - id-doża ta' manteniment tas-soltu hija bejn 1 mg u 2.5 mg kuljum.
English: Elimination
Maltese: Disġewsja
English: High blood pressure (hypertension) - The usual starting dose for adults is 1 mg per day.
Maltese: Pressjoni għolja tad-demm - Ġeneralment id-doża tal-bidu għall-adulti hija 1 mg kuljum.
English: (anemia, neutropenia, agranulocytosis and thrombocytopenia) - A type of severe allergic reaction (anaphylaxis) - Cerebral ischaemia, transient ischaemic attack, ischaemic stroke (may occur if blood pressure becomes too low) - Myocardial infarction (may occur if blood pressure becomes too low) - Irregular heartbeat - Interstitial lung disease - A disorder resembling systemic lupus erythematosus - Pins and needles or numbness in the hands or feet - Wheezing - A feeling of fullness or a throbbing pain behind the nose, cheeks and eyes (sinusitis).
Maltese: - Testijiet tad-demm li juru tnaqqis fl-għadd ta' ċelluli ħomor tad-demm, ċelluli bojod tad-demm jew plejtlets (anemija, newtropenija, agranuloċitosi u tromboċitopenija) - Tip ta' reazzjoni allerġika severa (anafilassi) - Iskemija ċerebrali, attakk iskemiku temporanju, puplesija iskemika (jistgħu jseħħu jekk il pressjoni tad-demm tkun baxxa wisq) - Infart mijokardijaku (jista' jseħħ jekk il-pressjoni tad-demm tkun baxxa wisq) - Taħbit tal-qalb irregolari - Marda tal-interstizju tal-pulmun - Disturb li jixbħu lil lupus erythematosus sistemiku - Tingiż jew tnemnim fl-idejn jew saqajn - Tħarħir - Sensazzjoni ta' konġestjoni jew uġigħ itektek wara l-imnieħer, ħaddejn u għajnejn (sinożite).
English: “Hypertension: The initial dose is 1 mg/day.
Maltese: Id-doża inizjali hija ta' 1 mg/jum.
English: Interstitial lung disease, bronchitis, sinusitis
Maltese: Marda tal-interstizju tal-pulmun, bronkite, sinożite
English: PACKAGE LEAFLET
Maltese: Mhux rakkomandata
English: Renal impairment
Maltese: Mhux irrakkomandat
English: Prior treatment with high dose diuretics may result in volume depletion and a risk of hypotension when initiating therapy with cilazapril (see section 4.4).
Maltese: Kura minn qabel b'doża għolja ta' dijuretiċi tista' twassal għal tnaqqis fil-volum u riskju ta' pressjoni baxxa meta tinbeda terapija b'cilazapril (ara sezzjoni 4.4).
English: Angioedema (may involve the face, lips, tongue, larynx or gastrointestinal tract) (see section 4.4) Rare
Maltese: Anġjoedima (tista' tinvolvi l-wiċċ, xufftejn, ilsien, larinġi jew apparat gastro-intestinali) (ara sezzjoni
English: If indicated, cilazaprilat, the active form of cilazapril, may be removed from the general circulation by haemodialysis (see section 4.4).”
Maltese: Jekk indikat, cilazaprilat, il-forma attiva ta' cilazapril, tista' titneħħa miċ-ċirkolazzjoni ġenerali permezz tal-emodjalisi (ara sezzjoni 4.4).”
English: Owing to the presence of lactose monohydrate, patients with hereditary galactose intolerance, Lapp lactase deficiency or glucose-galactose malabsorption should not take this medicine.
Maltese: Minħabba l-preżenza ta' lactose monohydrate, pazjenti b'intolleranza ereditarja għal galactose, defiċjenza Lapp lactase jew assorbiment ħażin ta' glucose-galactose m'għandhomx jieħdu din ilmediċina.
English: Vascace is indicated for the treatment of chronic heart failure.
Maltese: Vascace huwa indikat għall-kura ta' insuffiċjenza kronika tal-qalb.
English: Ul.
Maltese: Għeja
English: Vital signs, serum electrolytes and creatinine concentrations should be monitored continuously.
Maltese: Sinjali vitali, elettroliti fis-serum u l-konċentrazzjonijiet tal-krejatinina fis-serum għandhom jiġu ssorveljati kontinwament.
English: The demographic data justifies the efficacy in patients of various age, gender, and weight with mild to moderate primary hypertension.
Maltese: Id-dejta demografika tiġġustifika l-effikaċja fil-pazjenti ta' etajiet, sess, u piż differenti, bi pressjoni għolja primarja ħafifa sa moderata.
English: The use of ACE inhibitors such as cilazapril is contraindicated during the second and third trimester of pregnancy (see sections 4.3 and 4.4).
Maltese: L-użu ta' inibituri ACE bħal cilazapril huwa kontraindikat matul it-tieni u t-tielet trimestru tat-tqala (ara sezzjoni 4.3 u 4.4).
English: The efficacy of cilazapril in the treatment of hypertension has been documented in several clinical trials sponsored by Roche.
Maltese: L-effikaċja ta' cilazapril fit-trattament tal-pressjoni għolja ġiet iddokumentata f'bosta provi kliniċi sponsorjati minn Roche.
English: Routine monitoring of potassium and creatinine is part of normal medical practice for these patients.
Maltese: Monitoraġġ ta' rutina tal-potassju u tal-krejatinina hija parti millprattika medika normali għal dawn il-pazjenti.
English: - The other ingredient(s) is (are)...
Maltese: - Is-sustanza(i) l-oħra hi (huma) ....
English: Lupus-like syndrome (symptoms may include vasculitis, myalgia, arthralgia/arthritis, positive antinuclear antibodies, increased erythrocyte sedimentation rate, eosinophilia and leukocytosis) Nervous system disorders
Maltese: Sindrome li tixbaħ lil-lupus (sintomi jistgħu jinkludu vaskulite, uġigħ fil-muskoli, uġigħ filġogi/artrite, antikorpi antinukleari pożittiv, żjidiet fir-rata ta' sedimentazzjoni tal-eritroċiti, esinofilja u lewkoċitosi)
English: - Potassium supplements (including salt substitutes) or potassium-sparing diuretics.
Maltese: - Supplimenti tal-potassju (inkluż sostituti tal-melħ) jew dijuretiċi li ma jneħħux il-potassju.
English: PHARMACEUTICAL PARTICULARS 6.1 List of excipients [To be completed nationally] 6.2 Incompatibilities [To be completed nationally] 6.3 Shelf life [To be completed nationally] 6.4 Special precautions for storage [To be completed nationally] 6.5 Nature and contents of container [To be completed nationally]
Maltese: [Biex timtela mill-pajjiż partikolari] 6.2 Inkompatibilitajiet [Biex timtela mill-pajjiż partikolari]
English: The warning concerning anaphylaxis in dialysis patients receiving ACE inhibitors is discussed under a separate subheading in Section 4.4, “Anaphylaxis”.
Maltese: It-twissijiet li jirrigwardaw l-anafilassi fil-pazjenti tad-dijalisi li jkunu qegħdin jieħdu inibituri ACE hija diskussa taħt subintestatura separata fis-Sezzjoni 4.4, “Anafilassi”.
English: No clinically significant interactions were observed when cilazapril and digoxin, nitrates, coumarin anticoagulants, and H2 receptor blockers were concomitantly administered.
Maltese: Meta cilazapril u digoxin, nitrati, antikoagulanti coumarin, imblukkaturi tar-riċettur H2 ingħataw flimkien, ma kienux osservati interazzjonijiet ta' sinifikanza klinika.
English: Relatively limited evidence-based information is available on treatment of renovascular hypertension with ACE inhibitors (especially with cilazapril), but it cannot be ignored that ACE inhibitors are considered by many experts as effective medication for treatment of this condition.
Maltese: Teżisti informazzjoni relattivament limitata bbażata fuq levidenza dwar it-trattament ta' pressjoni għolja renovaskulari bl-inibituri ACE (b'mod speċjali b'cilazapril), iżda ma jistax jinjora li l-inibituri ACE jitqiesu minn bosta esperti bħala mediċina effettiva għat-trattament ta' din il-kondizzjoni.
English: Excess sweating, flushing, asthenia, sleep disorder (c) Description of selected adverse events
Maltese: Għaraq eċċessiv, fwawar, astenja, disturbi fl-irqad (ċ) Deskrizzjoni ta' avvenimenti avversi magħżula
English: The posolgy recommendation for cilazapril in chronic heart failure is based on effects on symptomatic improvement, rather than on data showing that cilazapril reduces morbidity and mortality in this patient group (see section 5.1).”
Maltese: Ir-rakkomandazzjoni tal-posoloġija għal cilazapril fl-insuffiċjenza kronika tal-qalb hija bbażata fuq leffetti fuq it-titjib sintomatiku, aktar milli fuq dejta li turi li cilazapril inaqqas il-morbidità u lmortalità f'dan il-grupp ta' pazjenti (ara sezzjoni 5.1).”
English: The haemodynamic and clinical effects occur promptly and persist.
Maltese: L-effetti emodinamiċi u kliniċi jseħħu fil-pront u jippersistu.
English: Treatment of chronic heart failure (CHF)
Maltese: Trattament ta' insuffiċjenza kronika tal-qalb
English: The posology recommendation for cilazapril in chronic heart failure is based on effects on symptomatic improvement, rather than on data showing that cilazapril reduces morbidity and mortality in this patient group (see section 5.1).
Maltese: Ir-rakkomandazzjoni tal-pożoloġija għal cilazapril f'insuffiċjenza kronika tal-qalb hija bbażata fuq l-effetti fuq it-titjib sintomatiku, u mhux fuq dejta li turi li cilazapril inaqqas il-morbożità u l-mortalità f'dan il-grupp ta' pazjenti (ara sezzjoni 5.1).
English: When pregnancy is diagnosed, treatment with ACE inhibitors should be stopped immediately, and, if appropriate, alternative therapy should be started (see sections 4.3 and 4.6).
Maltese: Meta ssir dijanjożi ta' tqala, il-kura b'inibituri ta' ACE għandha titwaqqaf minnufih, u jekk xieraq għandha tinbeda terapija alternattiva (ara sezzjonijiet 4.3 u 4.6).
English: FURTHER INFORMATION What Vascace contains - The active substance in Vascace is cilazapril.
Maltese: - Is-sustanza attiva f'Vascace hi cilazapril.
English: Treatment-related adverse events severe enough to stop treatment occur in less than 5% of patients receiving ACE inhibitors.
Maltese: Avvenimenti avversi relatati mal-kura severi biżżejjed biex titwaqqaf il-kura jseħħu f'inqas minn 5% tal-pazjenti li qed jirċievu inibituri ta' ACE.
English: The effect is usually not significant in patients with normal renal function.
Maltese: Leffett normalment ma jkunx sinifikanti f'pazjenti b'funzjoni tal-kliewi normali.
English: Limited data are available for overdosage in humans.
Maltese: Hemm dejta limitata disponibbli dwar doża eċċessiva fil-bnedmin.
English: Additional ADRs listed in local SPCs but not in the CDS have been included if appropriate references could be identified.
Maltese: ADRs oħrajn elenkati f'SPCs lokali iżda mhux fis-CDS ġew inklużi meta ġew identifikati referenzi xierqa.
English: Renal impairment, acute renal failure (see section 4.4), blood creatinine increased, blood urea increased
Maltese: Indeboliment tal-kliewi, insuffiċjenza akuta tal-kliewi (ara sezzjoni 4.4), żjieda tal-krejatinina fiddemm, żjieda tal-urea fid-demm
English: “Hypersensitivity to cilazapril or any components of the product, or to other ACE inhibitors History of angioedema associated with previous ACE inhibitor therapy Hereditary or idiopathic angioedema
Maltese: “Is-sensittività eċċessiva għal cilazapril jew kwalunkwe komponent tal-prodott, jew għal inibituri ACE oħrajn
English: In patients with renal artery stenosis, activation of the renin-angiotensin-aldosterone system helps to maintain renal perfusion by causing constriction of the efferent arteriole.
Maltese: Kienu rrappurtati wkoll effett tossiku fuq il-fetu, ittardjar tat-tkabbir filġuf u patent ductus arteriosus.
English: “Preclinical data reveal no special hazard for humans based on conventional studies of general pharmacology, repeated dose toxicity, genotoxicity, and carcinogenic potential.
Maltese: “Id-dejta preklinika ma turi l-ebda periklu speċjali għall-bnedmin abbażi ta' studji konvenzjonali dwar il-farmakoloġija ġenerali, it-tossiċità minn dożi ripetuti, il-ġenotossiċità, u l-potenzjal karċinoġeniku.
English: Hence, blockade of angiotensin II formation, and possibly also an increase in the formation of bradykinin, causes efferent arteriolar vasodilation resulting in a reduction in glomerular filtration pressure.
Maltese: Għalhekk, limblokk tal-formazzjoni ta' angiotensin II, u possibbilment ukoll żjieda fil-formazzjoni ta' bradykinin, jikkawżaw vażodilatazzjoni tal-arterjoli li ħerġin li twassal għal tnaqqis fil-pressjoni tal-filtrazzjoni glomerulari.
English: As with other agents acting on the renin-angiotensin system, there is an increased risk of renal insufficiency, including acute renal failure, when patients with renal artery stenosis are treated with cilazapril.
Maltese: Bħal b'sustanzi oħra li jaħdmu fuq is-sistema renin-angiotensin, hemm riskju akbar ta' insuffiċjenza tal-kliewi, inkluż insuffiċjenza akuta tal-kliewi, meta pazjenti bi stenosi tal-arterja tal-kliewi jiġu kkurati b'cilazapril.
English: QUALITATIVE AND QUANTITATIVE COMPOSITION For a full list of excipients, see section 6.1.
Maltese: U KWANTITATTIVA Għal-lista kompleta ta' sustanzi mhux attivi, ara sezzjoni 6.1. [Biex timtela mill-pajjiż partikolari]
English: Take special care with Vascace
Maltese: Oqgħod attent ħafna b'Vascace
English: Elderly patients: In elderly patients whose renal function is normal for age, plasma concentrations of cilazaprilat may be up to 40% higher and clearance 20% lower, than in younger patients.
Maltese: F'pazjenti anzjani li għandhom funzjoni tal-kliewi normali għall-età tagħhom, ilkonċentrazzjonijiet ta' cilazaprilat fil-plażma jistgħu jkunu sa 40% ogħla, u t-tneħħija 20% aktar baxxa, minn f'pazjenti iżgħar.
English: When pregnancy is diagnosed, treatment with ACE inhibitors should be stopped immediately, and, if appropriate, alternative therapy should be started.
Maltese: Meta tiġi ddijanjostikata t-tqala, ittrattament bl-inibituri ACE għandu jitwaqqaf minnufih, u, jekk ikun xieraq, għandha tinbeda terapija alternattiva.
English: At the request of the CHMP, interactions with other medicinal products (diuretics, tricyclic antidepressants, renal effects in non-steroidal anti-inflammatory drugs, sympathomimetics, anti-diabetics and gold) were also included in the harmonized SPC, in line with the other representatives of the drug class.
Maltese: Fuq it-talba tas-CHMP, l-effetti ma' prodotti mediċinali oħrajn (dijuretiċi, antidepressanti triċikliċi, effetti renali f'mediċini ta' kontra l-infjammazzjoni li mhumiex sterojdali, simpatomimetiċi, ta' kontra d-dijabete u d-deheb) kienu inklużi wkoll fl-SPC armonizzat, f'konformità mar-rappreżentanti oħrajn tal-klassi tal-mediċina.
English: Chronic heart failure - The usual starting dose is 0.5 mg per day.
Maltese: Insuffiċjenza kronika tal-qalb - Ġeneralment id-doża tal-bidu hija 0.5 mg kuljum.
English: If indicated, cilazaprilat, the active form of cilazapril, may be removed from the general circulation by haemodialysis (see section 4.4).
Maltese: Jekk indikat, cilazaprilat, il-forma attiva ta' cilazapril, jista' jitneħħa miċ-ċirkolazzjoni ġenerali permezz ta' emodijalisi (ara sezzjoni 4.4).
English: Renal impairment and acute renal failure are more likely in patients with severe heart failure, renal artery stenosis, pre-existing renal disorders or volume depletion (see section 4.4).
Maltese: Indeboliment tal-kliewi u insuffiċjenza akuta tal-kliewi huma aktar probabbli f'pazjenti b'insuffiċjenza severa tal-qalb, stenosi tal-arterja tal-kliewi, disturbi tal-kliewi eżistenti minn qabel jew tnaqqis talvolum (ara sezzjoni 4.4).
English: Cough
Maltese: Deheb
English: As recommended by the CHMP, the MAH has added an additional warning concerning the use of cilazapril in patients with high grade renal artery stenosis with renal impairment to the subsection entitled `Renal impairment' in section 4.4.
Maltese: Għalhekk, it-taħlita ta' cilazapril mal-mediċini msemmija fuq mhux irrakkomandata (ara sezzjoni 4.4).
English: The maximum daily dose for these patients is 5.0 mg.
Maltese: Id-doża massima ta' kuljum għal dawn il-pazjenti hija 5.0 mg.
English: Vascace is a specific, long-acting angiotensin-converting enzyme (ACE) inhibitor which suppresses the renin-angiotensin-aldosterone system and thereby the conversion of the inactive angiotensin I to angiotensin II, which is a potent vasoconstrictor.
Maltese: Vascace huwa inibitur speċifiku tal-enżima li tittrasforma angiotensin (ACE), li jaħdem fit-tul u li jrażżan is-sistema renin-angiotensin-aldosterone u b'hekk il-bidla ta' angiotensin I mhux attiv għal angiotensin II, li huwa vażokostrittur qawwi.
English: 1TW
Maltese: TAGĦRIF
English: Nausea
Maltese: Justor
English: Treatment of hypertension
Maltese: TAL-PRODOTT MEDIĊINALI
English: In particular, tell your doctor or pharmacist if you are taking any of the following medicines: - Diuretics (‘water tablets') - see ‘High blood pressure (hypertension)' in section 3 on ‘How to take Vascace'.
Maltese: - Dijuretiċi (‘pilloli tal-awrina') - ara ‘Pressjoni għolja tad-demm' f'sezzjoni 3 dwar ‘Kif għandek tieħu Vascace'.
English: “Elderly with hypertension: Treatment with Vascace should be initiated with a dose between 0.5 and 1.0 mg once daily.
Maltese: It-trattament b'Vascace għandu jinbeda b'doża bejn 0.5 u 1.0 mg darba kuljum.
English: Single cases of liver function disorders, such as increased values of liver function tests (transaminases, bilirubin, alkaline phosphatase, gamma GT) and cholestatic hepatitis with or without necrosis have been reported.
Maltese: Kienu irrappurtati każijiet uniċi ta' disturbi fil-funzjoni tal-fwied, bħal żjieda fil-valuri tat-testijiet talfunzjoni tal-fwied (transaminases, bilirubin, alkaline phosphatase, gamma GT) u epatite kolestatika bi jew mingħajr nekrosi.
English: In patients with chronic heart failure, the renin-angiotensin-aldosterone and sympathetic nervous systems are generally activated, leading to enhanced systemic vasoconstriction and promotion of sodium and water retention.
Maltese: F'pazjenti b'insuffiċjenza kronika tal-qalb, is-sistema renin-angiotensin-aldosterone u s-sistema simpatetika nervuża ġeneralment huma attivati, u jwasslu għal vażokostrizzjoni sistemika msaħħa u għall-promozzjoni ta' żamma tas-sodju u tal-ilma.
English: If you have an intolerance to lactose, talk to your doctor before taking this medicine.
Maltese: Jekk għandek intolleranza għal lactose, kellem lit-tabib tiegħek qabel tieħu din il-mediċina.
English: At-risk patients should start treatment with cilazapril under medical supervision, with a low initial dose and careful titration.
Maltese: Pazjenti f'riskju għandhom jibdew kura b'cilazapril taħt sorveljanza medika, b'doża tal-bidu baxxa u titrazzjoni b'attenzjoni.
English: In this leaflet:
Maltese: Emodijalisi:
English: By suppressing the renin-angiotensin-aldosterone system, Vascace improves loading conditions in the failing heart by reducing systemic vascular resistance (afterload) and pulmonary capillary wedge pressure (preload) in patients on diuretics and/or digitalis.
Maltese: Permezz tas-soppressjoni tas-sistema reninangiotensin-aldosterone, Vascace ittejjeb il-kundizzjonijiet ta' tagħbija fil-qalb li qed tbatti billi jnaqqas ir-reżistenza vaskulari sistematika (afterload) u l-pressjoni pulmonary capillary wedge (preload) f'pazjenti fuq dijuretiċi u/jew digitalis.
English: This belongs to a group of medicines called ‘ACE inhibitors' (Angiotensin Converting Enzyme Inhibitors).
Maltese: Dan jagħmel parti minn grupp ta' mediċini msejħa ‘inibituri ta' ACE' (Inibituri tal-Enżima li Tittrasforma lill-Angiotensin).